{"nctId":"NCT00386308","briefTitle":"Efficacy and Safety Study of XP12B in Women With Menorrhagia","startDateStruct":{"date":"2006-10"},"conditions":["Menorrhagia","Heavy Menstrual Bleeding"],"count":196,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Tranexamic acid tablets"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo tablets"]}],"interventions":[{"name":"Tranexamic acid tablets","otherNames":["Lysteda","XP12B"]},{"name":"Placebo tablets","otherNames":["Lysteda","XP12B"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Women with menorrhagia\n* 18-49 years of age\n* Regularly occurring menstrual periods\n\nExclusion Criteria:\n\n* History or presence of clinically significant disease or abnormalities that may confound the study\n* History of bilateral oophorectomy or hysterectomy\n* Hormone therapy","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"49 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Patient Reported Outcome Measure of Limitations in Social or Leisure Activities Associated With Heavy Menstrual Bleeding","description":"A positive unit change mean relects an improvement from baseline. Patient reported outcome scores had the following response categories: 1=not limited at all; 2=slightly limited; 3=moderately limited; 4=quite a bit limited; and 5=extremely limited","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"0.8"},{"groupId":"OG001","value":"0.4","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Patient Reported Outcome Measure of Limitations in Physical Activities Associated With Heavy Menstrual Bleeding","description":"A positive unit change mean relects an improvement from baseline. Patient reported outcome scores had the following response categories: 1=not limited at all; 2=slightly limited; 3=moderately limited; 4=quite a bit limited; and 5=extremely limited","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"0.9"},{"groupId":"OG001","value":"0.4","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Responder Analysis - Reduction in Large Stains","description":"Percentage of subjects who experienced a reduction from baseline in the frequency of large stains","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]}]},{"type":"PRIMARY","title":"Mean Reduction From Baseline in Menstrual Blood Loss (MBL)","description":"reduction of menstrual blood loss in mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":"64"},{"groupId":"OG001","value":"18","spread":"36"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":117},"commonTop":["Headache","Nasal & Sinus Symptoms","Back Pain","Abdominal Pain","Arthralgia"]}}}